Medical cannabis company Bod Australia (ASX:BDA) has increased its product line with the receipt of a new import permit.

On Tuesday (February 11), the cannabis company told investors that it has received approval from the New South Wales Department of Health and Office of Drug Control to import two new cannabidiol (CBD) isolate products with 2.5 percent and 10 percent strengths.


With the new offerings, which will be sold under Bod’s MediCabilis brand, the company will now have three products in the line. According to the firm, that gives it access to an additional 32 percent of the medicinal cannabis prescription market in Australia.

 

Introducing Our NEW Gold Outlook Report

   
BURSTING With Exclusive Information Not Found Anywhere Else. Don't Get Left Behind!
Grab Your FREE Gold Report Today!
 

Shares of Bod were up 3.7 percent from market close on Tuesday to the end of the trading session on Wednesday (February 12), ending the trading day at AU$0.28.

CEO Jo Patterson said in a statement that the new products are a result of the company’s considerable work in research and development.

“Bod is one of the only companies to have completed a Phase I clinical trial using a finished dose form and cannabis extract and this gives prescribers and patients tremendous confidence in our product,” the executive said.

The CBD isolate is derived from Bod’s exclusive full plant extract, which is also used in the original MediCabilis 5 percent CBD offering. The first of the products in the MediCabilis line has been prescribed over 2,000 times over the past 12 months, Bod said.

Patterson added that the products’ categorization as Schedule 4 substances means lower barriers for restrictions and use, further allowing the company to maximize its market penetration.

According to the Therapeutic Goods Association, the Schedule 4 category is designated for prescription-only medicines or prescription animal remedies.

Along with the first product in the MediCabilis line, the two new medicines will be available through the Special Access Scheme Category B pathway and through approved prescribers.

With the expanded line, Bod is confident that prescription volumes will rise in the coming months as patients and physicians seek out alternative treatments for pain, nausea and inflammatory conditions.

Apart from its operations within Australia, Bod’s international initiatives in its medical marijuana, hemp and CBD division are progressing as well, Patterson said.

In its report for the second fiscal quarter of 2020, Bod highlights the launch of its first CBD products to market in the UK through a partnership with Happiness Group (HKEX:1112).

Sales for Bod’s most recent quarter were at AU$536,000, bringing the total amount of sales in the first half of its fiscal 2020 year to AU$1.04 million. The firm noted that it had about AU$8.1 million in cash by the end of the quarter.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

  Life Science and Healthcare Investing in 2020 report cover

Coronavirus:An Overview for Investors

 
COVID-19 continues to impact world markets. Get INN’s overview of coronavirus investing.
 

Curaleaf Holdings, Inc. (CSE: CURA OTCQX: CURLF) (“Curaleaf” or the “Company”) a leading international provider of consumer products in cannabis, today announced that it will report its financial and operating results for the first quarter ended March 31, 2021 after market close on May 10, 2021 .

Management will host a conference call and audio webcast that evening at 5:00 p.m. ET consisting of prepared remarks followed by a question and answer session related to the Company’s operational and financial highlights.

Keep reading... Show less

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of two new stores, the Company’s 85 th and 86 th nationwide to commemorate the 50 th anniversary of 420, the holiday recognizing cannabis culture.

The new Florida dispensaries, the Company’s 80 th and 81 st in the state, located in Eustis and Palm Beach Gardens , further demonstrate Trulieve’s goal of ensuring direct, reliable access to medical cannabis across its home state.

Keep reading... Show less

CANBUD Distribution Corp. (CSE:CBDX, FSE:CD0) leverages on timely and methodical execution of its revenue generating plan. It operates a trinitarian enterprise model in the plant-based protein, psychedelic pharmaceutical and non-psychedelic nutraceutical, and hemp cannabinoids (CBD) spaces. (www.canbudcorp.com).

Keep reading... Show less

(TheNewswire)

Keep reading... Show less

Market entry will address pent-up demand in the Japanese & Philippine markets for TRACE proprietary plant-based mineral formulation and wellness-focused products

Emerging leader in innovative health and wellness beverages and natural products, BevCanna Enterprises Inc. ( CSE:BEV , Q:BVNNF , FSE:7BC ) (“ BevCanna ” or the “ Company ”) announces today that has entered into an exclusive sales agency distribution agreement with Yokohama-based Mirai Marketing Inc. (“Mirai”) to bring Naturo Group’s TRACE proprietary plant-based mineral consumer products to Mirai’s extensive Japanese and Philippine sales and distribution networks.

Keep reading... Show less